Lobeline

Last updated
Lobeline
Lobeline structure.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATCvet code
Identifiers
  • 2-((2R,6S)-6-((S)-2-Hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl)-1-phenylethanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.001.830 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C22H27NO2
Molar mass 337.463 g·mol−1
3D model (JSmol)
Melting point 130 to 131 °C (266 to 268 °F)
  • O=C(C[C@@H]1N([C@@H](CCC1)C[C@@H](C2=CC=CC=C2)O)C)C3=CC=CC=C3
  • InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1 X mark.svgN
  • Key:MXYUKLILVYORSK-HBMCJLEFSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Lobeline is a piperidine alkaloid found in a variety of plants, particularly those in the genus Lobelia , including Indian tobacco ( Lobelia inflata ), Devil's tobacco ( Lobelia tupa ), great lobelia ( Lobelia siphilitica ), Lobelia chinensis , and Hippobroma longiflora . In its pure form, it is a white amorphous powder which is freely soluble in water.

Contents

Potential uses

Lobeline has been sold, in tablet form, for use as a smoking cessation aid, but scientific research has not provided supporting evidence for this use. [1] [2] [3] Lobeline has also been studied for the treatment of other drug addictions such as addiction to amphetamines, [4] [5] cocaine, [6] or alcohol; [7] however, there is limited clinical evidence of any efficacy. [1] [8]

Toxicity

Ingestion of lobeline may cause nausea, vomiting, diarrhea, coughing, dizziness, visual disturbances, hearing disturbances, mental confusion, weakness, slowed heart rate, increased blood pressure, increased breathing rate, tremors, and seizures. [9] [10] Lobeline has a narrow therapeutic index: the potentially beneficial dose of lobeline is very close to the toxic dose. [9]

Pharmacology

Lobeline has multiple mechanisms of action, acting as a VMAT2 ligand, [11] [12] [13] which stimulates dopamine release to a moderate extent when administered alone, but reduces the dopamine release caused by methamphetamine. [14] [15] It also inhibits the reuptake of dopamine and serotonin, [16] and acts as a mixed agonist–antagonist at nicotinic acetylcholine receptors [17] [18] to which it binds at the subunit interfaces of the extracellular domain. [19] It is also an antagonist at μ-opioid receptors. [20] It seems to be a P-glycoprotein inhibitor, according to at least one study. [21] It has been hypothesized that P-glycoprotein inhibition reduces chemotherapeutic resistance in cancer, [22] presumably affecting any substrates of P-gp.

Analogous compounds, such as lobelane (a minor alkaloid found in the same plants) and its synthetic derivatives have similar biological effects with somewhat different relative affinities to VMAT and other proteins. [23] A related alkaloid sedamine, [24] with only one 2-phenylethyl group on the piperidine ring and found in plants of genus sedum, is known to be an inhibitor of pea seedlings amine oxidase, [25] but its affinity to proteins such as the dopamine transporter has apparently not been tested.

See also

Related Research Articles

<i>Lobelia</i> Genus of flowering plants

Lobelia is a genus of flowering plants in the family Campanulaceae comprising 415 species, with a subcosmopolitan distribution primarily in tropical to warm temperate regions of the world, a few species extending into cooler temperate regions. They are known generally as lobelias.

<span class="mw-page-title-main">Monoamine transporter</span> Proteins that function as integral plasma-membrane transporters

Monoamine transporters (MATs) are proteins that function as integral plasma-membrane transporters to regulate concentrations of extracellular monoamine neurotransmitters. The three major classes are serotonin transporters (SERTs), dopamine transporters (DATs), and norepinephrine transporters (NETs) and are responsible for the reuptake of their associated amine neurotransmitters. MATs are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. MAT regulation generally occurs through protein phosphorylation and post-translational modification. Due to their significance in neuronal signaling, MATs are commonly associated with drugs used to treat mental disorders as well as recreational drugs. Compounds targeting MATs range from medications such as the wide variety of tricyclic antidepressants, selective serotonin reuptake inhibitors such as fluoxetine (Prozac) to stimulant medications such as methylphenidate (Ritalin) and amphetamine in its many forms and derivatives methamphetamine (Desoxyn) and lisdexamfetamine (Vyvanse). Furthermore, drugs such as MDMA and natural alkaloids such as cocaine exert their effects in part by their interaction with MATs, by blocking the transporters from mopping up dopamine, serotonin, and other neurotransmitters from the synapse.

The vesicular monoamine transporter (VMAT) is a transport protein integrated into the membranes of synaptic vesicles of presynaptic neurons. It transports monoamine neurotransmitters – such as dopamine, serotonin, norepinephrine, epinephrine, and histamine – into the vesicles, which release the neurotransmitters into synapses, as chemical messages to postsynaptic neurons. VMATs utilize a proton gradient generated by V-ATPases in vesicle membranes to power monoamine import.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine" (literally, "working on dopamine"), dopamine being a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain. Dopaminergic brain pathways facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as dopaminergic. Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol O-methyl transferase (COMT) may be referred to as dopaminergic as well. Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have dopaminergic effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT2.

<span class="mw-page-title-main">SKF-82,958</span> Chemical compound

SKF-82,958 is a synthetic compound of the benzazepine class that acts as a D1/D5 receptor full agonist. SKF-82,958 and similar D1-like-selective full agonists like SKF-81,297 and 6-Br-APB produce characteristic anorectic effects, hyperactivity and self-administration in animals, with a similar but not identical profile to that of dopaminergic stimulants such as amphetamine. SKF-82,958 was also subsequently found to act as an agonist of ERα with negligible activity at ERβ, making it a subtype-selective estrogen.

<span class="mw-page-title-main">18-Methoxycoronaridine</span> Chemical compound

18-Methoxycoronaridine, also known as zolunicant, is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemists Upul K. Bandarage and Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine, nicotine and sucrose. It has also been shown to produce anorectic effects in obese rats, most likely due to the same actions on the reward system which underlie its anti-addictive effects against drug addiction.

<span class="mw-page-title-main">Vesicular monoamine transporter 2</span> Mammalian protein found in Homo sapiens

The solute carrier family 18 member 2 (SLC18A2) also known as vesicular monoamine transporter 2 (VMAT2) is a protein that in humans is encoded by the SLC18A2 gene. SLC18A2 is an integral membrane protein that transports monoamines—particularly neurotransmitters such as dopamine, norepinephrine, serotonin, and histamine—from cellular cytosol into synaptic vesicles. In nigrostriatal pathway and mesolimbic pathway dopamine-releasing neurons, SLC18A2 function is also necessary for the vesicular release of the neurotransmitter GABA.

<span class="mw-page-title-main">Trace amine</span> Amine receptors in the mammalian brain

Trace amines are an endogenous group of trace amine-associated receptor 1 (TAAR1) agonists – and hence, monoaminergic neuromodulators – that are structurally and metabolically related to classical monoamine neurotransmitters. Compared to the classical monoamines, they are present in trace concentrations. They are distributed heterogeneously throughout the mammalian brain and peripheral nervous tissues and exhibit high rates of metabolism. Although they can be synthesized within parent monoamine neurotransmitter systems, there is evidence that suggests that some of them may comprise their own independent neurotransmitter systems.

<i>Lobelia tupa</i> Species of plant

Lobelia tupa is a species of Lobelia native to central Chile from Valparaíso south to Los Lagos regions.

<span class="mw-page-title-main">Phenyltropane</span> Class of chemical compounds

Phenyltropanes (PTs) were originally developed to reduce cocaine addiction and dependency. In general these compounds act as inhibitors of the plasmalemmal monoamine reuptake transporters. This research has spanned beyond the last couple decades, and has picked up its pace in recent times, creating numerous phenyltropanes as research into cocaine analogues garners interest to treat addiction.

<span class="mw-page-title-main">(+)-CPCA</span> Stimulant drug

(+)-CPCA is a stimulant drug similar in structure to pethidine and to RTI-31, but nocaine is lacking the two-carbon bridge of RTI-31's tropane skeleton. This compound was first developed as a substitute agent for cocaine.

A serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of drug that acts as a combined reuptake inhibitor of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. It does this by concomitantly inhibiting the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), respectively. Inhibition of the reuptake of these neurotransmitters increases their extracellular concentrations and, therefore, results in an increase in serotonergic, adrenergic, and dopaminergic neurotransmission. The naturally-occurring and potent SNDRI cocaine is widely used recreationally and often illegally for the euphoric effects it produces.

<span class="mw-page-title-main">TAAR1</span> Protein-coding gene in the species Homo sapiens

Trace amine-associated receptor 1 (TAAR1) is a trace amine-associated receptor (TAAR) protein that in humans is encoded by the TAAR1 gene. TAAR1 is an intracellular amine-activated Gs-coupled and Gq-coupled G protein-coupled receptor (GPCR) that is primarily expressed in several peripheral organs and cells, astrocytes, and in the intracellular milieu within the presynaptic plasma membrane of monoamine neurons in the central nervous system (CNS). TAAR1 was discovered in 2001 by two independent groups of investigators, Borowski et al. and Bunzow et al. TAAR1 is one of six functional human trace amine-associated receptors, which are so named for their ability to bind endogenous amines that occur in tissues at trace concentrations. TAAR1 plays a significant role in regulating neurotransmission in dopamine, norepinephrine, and serotonin neurons in the CNS; it also affects immune system and neuroimmune system function through different mechanisms.

<span class="mw-page-title-main">Reuptake inhibitor</span> Type of drug

Reuptake inhibitors (RIs) are a type of reuptake modulators. It is a drug that inhibits the plasmalemmal transporter-mediated reuptake of a neurotransmitter from the synapse into the pre-synaptic neuron. This leads to an increase in extracellular concentrations of the neurotransmitter and an increase in neurotransmission. Various drugs exert their psychological and physiological effects through reuptake inhibition, including many antidepressants and psychostimulants.

<span class="mw-page-title-main">RTI-126</span> Pharmaceutical drug

RTI-126 is a phenyltropane derivative which acts as a potent monoamine reuptake inhibitor and stimulant drug, and has been sold as a designer drug. It is around 5 times more potent than cocaine at inhibiting monoamine reuptake in vitro, but is relatively unselective. It binds to all three monoamine transporters, although still with some selectivity for the dopamine transporter. RTI-126 has a fast onset of effects and short duration of action, and its pharmacological profile in animals is among the closest to cocaine itself out of all the drugs in the RTI series. Its main application in scientific research has been in studies investigating the influence of pharmacokinetics on the abuse potential of stimulant drugs, with its rapid entry into the brain thought to be a key factor in producing its high propensity for development of dependence in animals.

<span class="mw-page-title-main">Monoamine releasing agent</span> Class of compounds

A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of a monoamine neurotransmitter from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitter. Many drugs induce their effects in the body and/or brain via the release of monoamine neurotransmitters, e.g., trace amines, many substituted amphetamines, and related compounds.

<span class="mw-page-title-main">RTI-113</span> Chemical compound

RTI(-4229)-113 is a stimulant drug which acts as a potent and fully selective dopamine reuptake inhibitor (DRI). It has been suggested as a possible substitute drug for the treatment of cocaine addiction. "RTI-113 has properties that make it an ideal medication for cocaine abusers, such as an equivalent efficacy, a higher potency, and a longer duration of action as compared to cocaine." Replacing the methyl ester in RTI-31 with a phenyl ester makes the resultant RTI-113 fully DAT specific. RTI-113 is a particularly relevant phenyltropane cocaine analog that has been tested on squirrel monkeys. RTI-113 has also been tested against cocaine in self-administration studies for DAT occupancy by PET on awake rhesus monkeys. The efficacy of cocaine analogs to elicit self-administration is closely related to the rate at which they are administered. Slower onset of action analogs are less likely to function as positive reinforcers than analogues that have a faster rate of onset.

<span class="mw-page-title-main">RTI-51</span> Chemical compound

(–)-2β-Carbomethoxy-3β-(4-bromophenyl)tropane is a semi-synthetic alkaloid in the phenyltropane group of psychostimulant compounds. First publicized in the 1990s, it has not been used enough to have gained a fully established profile. RTI-51 can be expected to have properties lying somewhere in between RTI-31 and RTI-55. It has a ratio of monoamine reuptake inhibition of dopamine > serotonin > norepinephrine which is an unusual balance of effects not produced by other commonly used compounds. It has been used in its 76Br radiolabelled form to map the distribution of dopamine transporters in the brain.

A monoamine reuptake inhibitor (MRI) is a drug that acts as a reuptake inhibitor of one or more of the three major monoamine neurotransmitters serotonin, norepinephrine, and dopamine by blocking the action of one or more of the respective monoamine transporters (MATs), which include the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). This in turn results in an increase in the synaptic concentrations of one or more of these neurotransmitters and therefore an increase in monoaminergic neurotransmission.

<span class="mw-page-title-main">Nornicotine</span> Chemical compound

Nornicotine is an alkaloid found in various plants including Nicotiana, the tobacco plant. It is chemically similar to nicotine, but does not contain a methyl group.

References

  1. 1 2 Stead LF, Hughes JR (February 2012). "Lobeline for smoking cessation". The Cochrane Database of Systematic Reviews. 2012 (2): CD000124. doi:10.1002/14651858.CD000124.pub2. PMC   7043274 . PMID   22336780. On the basis of the trials which have been published in the past sixty years there is no evidence that lobeline has any long term effect on smoking cessation.
  2. Marlow SP, Stoller JK (December 2003). "Smoking cessation". Respiratory Care. 48 (12): 1238–54, discussion 1254–6. PMID   14651764.
  3. Buchhalter AR, Fant RV, Henningfield JE (2008). "Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status". Drugs. 68 (8): 1067–88. doi:10.2165/00003495-200868080-00005. PMID   18484799. S2CID   46875770.
  4. Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, Bardo MT (September 2007). "Lobelane decreases methamphetamine self-administration in rats". European Journal of Pharmacology. 571 (1): 33–8. doi:10.1016/j.ejphar.2007.06.003. PMC   2104779 . PMID   17612524.
  5. Eyerman DJ, Yamamoto BK (January 2005). "Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum". The Journal of Pharmacology and Experimental Therapeutics. 312 (1): 160–9. doi:10.1124/jpet.104.072264. PMID   15331654. S2CID   19787823.
  6. Polston JE, Cunningham CS, Rodvelt KR, Miller DK (August 2006). "Lobeline augments and inhibits cocaine-induced hyperactivity in rats". Life Sciences. 79 (10): 981–90. doi:10.1016/j.lfs.2006.05.006. PMID   16765386.
  7. Farook JM, Lewis B, Gaddis JG, Littleton JM, Barron S (June 2009). "Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice". Physiology & Behavior. 97 (3–4): 503–6. doi:10.1016/j.physbeh.2009.02.031. PMID   19268674. S2CID   23762679.
  8. "Lobelia". drugs.com.
  9. 1 2 "Lobelia". drugs.com.
  10. "Symptoms of Plant poisoning -- Lobeline".
  11. Zheng G, Dwoskin LP, Crooks PA (November 2006). "Vesicular monoamine transporter 2: role as a novel target for drug development". The AAPS Journal. 8 (4): E682-92. doi:10.1208/aapsj080478. PMC   2751365 . PMID   17233532.
  12. Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA (April 2007). "Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2". Bioorganic & Medicinal Chemistry. 15 (8): 2975–92. doi:10.1016/j.bmc.2007.02.013. PMC   2001191 . PMID   17331733.
  13. Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA (August 2005). "Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter". Journal of Medicinal Chemistry. 48 (17): 5551–60. doi:10.1021/jm0501228. PMC   3617589 . PMID   16107155.
  14. Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A (March 2008). "Lobeline effects on tonic and methamphetamine-induced dopamine release". Biochemical Pharmacology. 75 (6): 1411–5. doi:10.1016/j.bcp.2007.11.019. PMC   2435375 . PMID   18191815.
  15. Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A (September 2004). "Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system". The Journal of Pharmacology and Experimental Therapeutics. 310 (3): 1142–51. doi:10.1124/jpet.104.067314. PMID   15102929. S2CID   1315645.
  16. Zheng G, Horton DB, Deaciuc AG, Dwoskin LP, Crooks PA (October 2006). "Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters". Bioorganic & Medicinal Chemistry Letters. 16 (19): 5018–21. doi:10.1016/j.bmcl.2006.07.070. PMC   3934794 . PMID   16905316.
  17. Damaj MI, Patrick GS, Creasy KR, Martin BR (July 1997). "Pharmacology of lobeline, a nicotinic receptor ligand". The Journal of Pharmacology and Experimental Therapeutics. 282 (1): 410–9. PMID   9223582.
  18. Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, Dwoskin LP (January 2003). "Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats". Pharmacology, Biochemistry, and Behavior. 74 (2): 279–86. doi:10.1016/s0091-3057(02)00996-6. PMID   12479946. S2CID   20510311.
  19. PDB entry 2bys . Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y (October 2005). "Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations". The EMBO Journal. 24 (20): 3635–46. doi:10.1038/sj.emboj.7600828. PMC   1276711 . PMID   16193063.
  20. Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR (July 2007). "Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists". Drug and Alcohol Dependence. 89 (2–3): 282–91. doi:10.1016/j.drugalcdep.2007.02.003. PMID   17368966.
  21. Ma Y, Wink M (September 2008). "Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells". Phytomedicine. 15 (9): 754–8. doi:10.1016/j.phymed.2007.11.028. PMID   18222670.
  22. Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM (January 2015). "P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review". Journal of Advanced Research. 6 (1): 45–62. doi:10.1016/j.jare.2014.11.008. PMC   4293676 . PMID   25685543.
  23. Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP (September 2004). "Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters". The Journal of Pharmacology and Experimental Therapeutics. 310 (3): 1035–45. doi:10.1124/jpet.104.068098. PMID   15121762. S2CID   438066.
  24. "(-)-Sedamine, CID=442657". PubChem Database. National Center for Biotechnology Information. Retrieved July 7, 2019.
  25. Adámková S, Frébort I, Sebela M, Pec P (October 2001). "Probing the active site of pea seedlings amine oxidase with optical antipodes of sedamine alkaloids". Journal of Enzyme Inhibition. 16 (4): 367–72. doi: 10.1080/14756360109162385 . PMID   11916142.